AR061446A1 - Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico - Google Patents

Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico

Info

Publication number
AR061446A1
AR061446A1 ARP070102566A ARP070102566A AR061446A1 AR 061446 A1 AR061446 A1 AR 061446A1 AR P070102566 A ARP070102566 A AR P070102566A AR P070102566 A ARP070102566 A AR P070102566A AR 061446 A1 AR061446 A1 AR 061446A1
Authority
AR
Argentina
Prior art keywords
manufacture
treatment
dimethylxantine
anioious
neuropsychiatric disorder
Prior art date
Application number
ARP070102566A
Other languages
English (en)
Original Assignee
Pf Medicament
Univ Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, Univ Rouen filed Critical Pf Medicament
Publication of AR061446A1 publication Critical patent/AR061446A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Abstract

Una utilizacion de la paraxantina para la fabricacion de un medicamento psicoanaléptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiátrico
ARP070102566A 2006-06-12 2007-06-12 Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico AR061446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605189A FR2902010B1 (fr) 2006-06-12 2006-06-12 Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique

Publications (1)

Publication Number Publication Date
AR061446A1 true AR061446A1 (es) 2008-08-27

Family

ID=37592447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102566A AR061446A1 (es) 2006-06-12 2007-06-12 Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico

Country Status (8)

Country Link
US (1) US20090325984A1 (es)
EP (1) EP2026812A1 (es)
JP (1) JP2009539921A (es)
AR (1) AR061446A1 (es)
CA (1) CA2654891A1 (es)
FR (1) FR2902010B1 (es)
TW (1) TW200815013A (es)
WO (1) WO2007144315A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014065446A1 (ko) * 2012-10-24 2014-05-01 (주)라이프앤진 카페인과 파라잔틴에 의한 지방 분해 슬리밍 조성물
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
AU2021210442A1 (en) * 2020-01-23 2022-09-15 Ingenious Ingredients, LP Paraxanthine-based bioactive composition and method of use thereof
US20230355632A1 (en) * 2020-09-14 2023-11-09 Lennham Pharmaceuticals, Inc. Deuterated paraxanthine and uses thereof
EP4312802A1 (en) * 2021-03-26 2024-02-07 Px Ing, Llc The use of paraxanthine to reduce exercise-induced mental fatigue
JP2024513831A (ja) * 2021-03-31 2024-03-27 ピーエックス・アイエヌジー，エルエルシー ビデオゲーマーのパフォーマンスを改善するためのパラキサンチンの使用
WO2022232469A1 (en) 2021-04-29 2022-11-03 Revel Technologies, Inc. Compositions and methods for their production
US20230037138A1 (en) * 2021-07-27 2023-02-02 Ingenious Ingredients, LP Paraxanthine-based caffeine substitute compositions and method of use thereof in slow caffeine metabolizers
CA3234492A1 (en) * 2021-10-12 2023-04-20 Ralf Jager Dileucine compositions and methods of use thereof for fat loss
US20230165868A1 (en) * 2021-11-28 2023-06-01 Ingenious Ingredients, LP Paraxanthine-based compositions for enhancing muscle function, nitric oxide signaling, and/or muscle glycogen levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189717B2 (en) * 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
ATE433993T1 (de) * 2003-02-26 2009-07-15 Univ Johns Hopkins Modulatorische verbindungen und verfahren für glutamattransport
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
JP2009528059A (ja) * 2006-02-28 2009-08-06 メタボロン インコーポレイテッド 筋萎縮性側索硬化症に関するバイオマーカー及びそれらを使用する方法

Also Published As

Publication number Publication date
JP2009539921A (ja) 2009-11-19
EP2026812A1 (en) 2009-02-25
FR2902010A1 (fr) 2007-12-14
CA2654891A1 (en) 2007-12-21
TW200815013A (en) 2008-04-01
WO2007144315A1 (en) 2007-12-21
FR2902010B1 (fr) 2008-08-22
US20090325984A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
MX2008001546A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de una enfermedad proliferativa o una inflamacion.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
BRPI0919694A2 (pt) composto, composto farmacêutica, uso de um composto, e, método de tratamento de uma doença.
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007001779A1 (es) Compuestos triciclicos, con afinidad superior por los receptores de melatonina; composicion farmaceutica; util para la profilaxis o tratamiento de la enfermedad del sueno y compuestos intermediarios.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal